# A Study To Examine The Safety, Tolerability And Pharmacokinetics Of PF-02545920 In Psychiatrically Stable Subjects With Schizophrenia

> **NCT01829048** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 37 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** PF-02545920
- **DRUG:** PF-02545920
- **DRUG:** PF-02545920
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01829048
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-03-06
- **Primary completion:** 2013-10-17
- **Final completion:** 2013-10-17
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2018-08-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01829048

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01829048, "A Study To Examine The Safety, Tolerability And Pharmacokinetics Of PF-02545920 In Psychiatrically Stable Subjects With Schizophrenia". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01829048. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*